Immuneering Corporation Class A Common Stock
IMRXStock
$4.78+24.94%52W
Market Cap$333.84M
P/E—
Div yield—
Beta0.25
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-31.15%
Price vs S&P 500 (4W)24.74%
VGM Score36.40
Market Capitalization$333.84M
Earnings Surprise History
Q1 26-0.21est. -0.26
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.25
4.25
4.25
4.25
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IMRXImmuneering Corporation Class A Common Stock | D | — | C | $4.78 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Immuneering is a biopharmaceutical company developing oncology and neurology treatments using its proprietary Disease Cancelling Technology platform, which leverages computational biology and translational bioinformatics. The company generates revenue from both internal drug discovery programs and by licensing its computational capabilities to other pharmaceutical and biotechnology companies.